RU-2026112360-A - New Combination Therapy for Blood Cancer

Inventors

• ЭНДО, Хироко
• ФУРУИТИ, Хацуо
• НИСИОКА, Ю
• САВА, Масааки

Assignees

• КАРНА БАЙОСАЙЕНСИЗ, ИНК.

Dates

Publication Date

20260505

Application Date

20240926

Priority Date

20230927

Claims (20)

1. 1. A pharmaceutical composition comprising compound (I):
2. or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient, which is administered to a patient in combination with a DNA methyltransferase inhibitor for use in the treatment of blood cancer.
3. 2. The pharmaceutical composition according to claim 1, which is also administered to a patient in combination with a BCL-2 inhibitor in addition to a DNA methyltransferase inhibitor for use in the treatment of blood cancer.
4. 3. The pharmaceutical composition according to claim 1 or 2, wherein the blood cancer is myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML).
5. 4. The pharmaceutical composition according to claim 1 or 2, wherein the blood cancer is myelodysplastic syndrome (MDS).
6. 5. The pharmaceutical composition according to claim 1 or 2, wherein the blood cancer is acute myeloid leukemia (AML).
7. 6. The pharmaceutical composition according to claim 1 or 2, wherein the DNA methyltransferase inhibitor is a pharmaceutical composition comprising azacitidine or a pharmaceutically acceptable salt or hydrate thereof, or decitabine or a pharmaceutically acceptable salt or hydrate thereof, as an active ingredient.
8. 7. The pharmaceutical composition of claim 6, wherein the DNA methyltransferase inhibitor is a pharmaceutical composition comprising azacitidine or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient.
9. 8. The pharmaceutical composition of claim 6, wherein the DNA methyltransferase inhibitor is a pharmaceutical composition comprising decitabine or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient.
10. 9. The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition comprising azacitidine or its pharmaceutically acceptable salt or hydrate as an active ingredient, and the pharmaceutical composition comprising compound (I) or its pharmaceutically acceptable salt or hydrate as an active ingredient, are administered both simultaneously and separately and sequentially.
11. 10. The pharmaceutical composition according to claim 8, wherein the pharmaceutical composition comprising decitabine or its pharmaceutically acceptable salt or hydrate as an active ingredient, and the pharmaceutical composition comprising compound (I) or its pharmaceutically acceptable salt or hydrate as an active ingredient, are administered both simultaneously and separately and sequentially.
12. 11. The pharmaceutical composition of claim 2, wherein the BCL-2 inhibitor is a pharmaceutical composition comprising venetoclax or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient.
13. 12. The pharmaceutical composition according to any one of claims 9-11, wherein the blood cancer is myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML).
14. 13. The pharmaceutical composition according to claim 12, wherein the blood cancer is myelodysplastic syndrome (MDS).
15. 14. The pharmaceutical composition of claim 12, wherein the blood cancer is acute myeloid leukemia (AML).
16. 15. A kit comprising a pharmaceutical composition comprising a DNA methyltransferase inhibitor and compound (I) or a pharmaceutically acceptable salt or hydrate thereof, each as an active ingredient, for use in combination administration as defined in paragraph 1.
17. 16. A kit comprising a pharmaceutical composition comprising a DNA methyltransferase inhibitor, a BCL-2 inhibitor and compound (I) or a pharmaceutically acceptable salt or hydrate thereof, each as an active ingredient, for use in combination administration as defined in paragraph 2.
18. 17. A method for treating blood cancer, comprising administering to a patient a pharmaceutical composition comprising compound (I) or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient, in combination with a DNA methyltransferase inhibitor.
19. 18. A method for treating blood cancer, comprising administering to a patient a pharmaceutical composition comprising compound (I) or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient, in combination with a DNA methyltransferase inhibitor and a BCL-2 inhibitor.
20. 19. The method according to claim 17 or 18, wherein the blood cancer is myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML).